12:57 PM
Apr 12, 2019
 |  BC Extra  |  Company News

Gilead, Novo team up to combine NASH compounds

Editor's Note: This article was updated on Apr 12, 2019 at 1:38 PM PDT

A day after Gilead presented Phase II data at EASL for its cilofexor plus firsocostat combination to treat non-alcoholic steatohepatitis, the company partnered with Novo Nordisk to test the duo in combination with semaglutide in a clinical trial, totting up another combo partnership in the hot NASH field.

Dealmaking to create combinations has become a core component of pharmas’ strategies for NASH, because the consensus view is that no single therapy can control the multifactorial processes driving most patients’ disease (see "New Partners for NASH").

Read the full 407 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >